

ABSTRACT

Antibodies specific for c-Met, a protein tyrosine kinase whose ligand is hepatocyte growth factor (HGF), are provided. The antibodies and fragments  
5 thereof may block binding of HGF to c-Met. Antagonist antibodies can be employed to block binding of HGF to c-Met or substantially inhibit c-Met activation. The c-Met antibodies may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer, pathological liver conditions, and ophthalmic diseases using the c-Met  
10 antibodies are also provided.